AVITA Medical to Host Investor Webinar Briefing
AVITA Medical (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company, will host an investor webinar briefing on May 21, 2024, at 4:00 p.m. PDT. The event will feature presentations from CEO Jim Corbett and CFO David O'Toole, focusing on financial and business results from the recent Q1 2024 earnings webcast. A Q&A session will follow the main presentation. Interested parties can register via a provided Zoom link and submit questions either through the registration page or during the webinar. A replay will be available on AVITA's website after the event.
- Company is actively engaging with shareholders and prospective investors.
- The investor webinar will provide insights into financial and business outcomes from Q1 2024.
- CEO and CFO participation indicates a comprehensive overview and authoritative information.
- The Q&A session allows for direct interaction with top executives.
- Replay availability ensures information is accessible to those who cannot attend live.
- No new financial data or major business developments announced in this PR.
- The content could be perceived as a routine update, lacking substantive new information.
- Potentially impact on stock due to absence of significant news or updates.
- Scheduling constraints may limit live participation from some investors due to time zone differences.
VALENCIA, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on May 21, 2024, at 4:00 p.m. Pacific Daylight Time / May 22, 2024, at 9:00 a.m. Australian Eastern Standard Time.
The webinar presentation will cover financial and business results from our recent first quarter 2024 earnings webcast and conclude with a Q&A session.
To register for the presentation, please follow this Zoom link:
https://us02web.zoom.us/webinar/register/5817086771005/WN_yN29KwqiQiWKgx9HPMzaSg
Participants are invited to submit questions via the registration page or during the webinar via the chat function. A replay will be available on the AVITA Medical website, ir.avitamedical.com, following the presentation.
About AVITA Medical, Inc.
AVITA Medical® is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, in the United States.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE-mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
FAQ
When is the AVITA Medical investor webinar briefing?
Who will present at the AVITA Medical investor webinar?
What topics will be covered in the AVITA Medical investor webinar?
How can I register for the AVITA Medical investor webinar?
Will there be a replay available for the AVITA Medical investor webinar?
